inchikey,name,score,descriptions,links
KBOPZPXVLCULAV-UHFFFAOYSA-N,KBOPZPXVLCULAV-UHFFFAOYSA-N,0,"None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).",Immunomodulatory;Patrick;https://www.nature.com/articles/s41421-020-0153-3
XFCLJVABOIYOMF-QPLCGJKRSA-N,XFCLJVABOIYOMF-QPLCGJKRSA-N,1,"None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).;Effective against SARS-CoV MERS-CoV in vitro / inhibits EVOB entry in cells / identified in network screening",Viral entry;Viral entry;Patrick;Miquel/Gemma;https://www.nature.com/articles/s41421-020-0153-3;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136000/
JUKPWJGBANNWMW-VWBFHTRKSA-N,JUKPWJGBANNWMW-VWBFHTRKSA-N,1,"None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).;Prolongs survival, tested in viral myocarditis in mice",Immunomodulatory;Immunomodulatory;Patrick;Miquel/Gemma;https://www.nature.com/articles/s41421-020-0153-3;https://www.ncbi.nlm.nih.gov/pubmed/19213804
AHOUBRCZNHFOSL-YOEHRIQHSA-N,AHOUBRCZNHFOSL-YOEHRIQHSA-N,0,"None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).",Unknown;Patrick;https://www.nature.com/articles/s41421-020-0153-3
QFJCIRLUMZQUOT-HPLJOQBZSA-N,QFJCIRLUMZQUOT-HPLJOQBZSA-N,2,"None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).;MERS-CoV 60% decreased infection in vitro / improved clinical outcome H1N1;Inhibits MERS replication in vitro;Drugs from Sars-Cov-2-Human PPI map",Host factor;Immunomodulatory;Host factor;Immunomodulatory;Patrick;Miquel/Gemma;Miquel/Gemma;Victor;https://www.nature.com/articles/s41421-020-0153-3;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733787;https://www.ncbi.nlm.nih.gov/pubmed/25487801;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
RJURFGZVJUQBHK-IIXSONLDSA-N,RJURFGZVJUQBHK-IIXSONLDSA-N,0,"None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).",Unknown;Patrick;https://www.nature.com/articles/s41421-020-0153-3
YOSHYTLCDANDAN-UHFFFAOYSA-N,YOSHYTLCDANDAN-UHFFFAOYSA-N,1,"None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).;identified in network screening",Viral entry;Viral entry;Patrick;Miquel/Gemma;https://www.nature.com/articles/s41421-020-0153-3;https://www.nature.com/articles/s41421-020-0153-3
GLVAUDGFNGKCSF-UHFFFAOYSA-N,GLVAUDGFNGKCSF-UHFFFAOYSA-N,0,"None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).",Immunomodulatory;Patrick;https://www.nature.com/articles/s41421-020-0153-3
DRLFMBDRBRZALE-UHFFFAOYSA-N,DRLFMBDRBRZALE-UHFFFAOYSA-N,1,"None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).;Prolongs survival due to anti inflammation (not virus related)",Immunomodulatory;Immunomodulatory;Patrick;Miquel/Gemma;https://www.nature.com/articles/s41421-020-0153-3;https://www.nature.com/articles/s41421-020-0153-3
GPKJTRJOBQGKQK-UHFFFAOYSA-N,GPKJTRJOBQGKQK-UHFFFAOYSA-N,0,"None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).",Viral entry;Patrick;https://www.nature.com/articles/s41421-020-0153-3
OGHNVEJMJSYVRP-UHFFFAOYSA-N,OGHNVEJMJSYVRP-UHFFFAOYSA-N,0,"None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).",Immunomodulatory;Patrick;https://www.nature.com/articles/s41421-020-0153-3
IAKHMKGGTNLKSZ-INIZCTEOSA-N,IAKHMKGGTNLKSZ-INIZCTEOSA-N,0,"None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).",Unknown;Patrick;https://www.nature.com/articles/s41421-020-0153-3
DSSYKIVIOFKYAU-UHFFFAOYSA-N,DSSYKIVIOFKYAU-UHFFFAOYSA-N,0,"None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).",Viral entry;Patrick;https://www.nature.com/articles/s41421-020-0153-3
WKRLQDKEXYKHJB-HFTRVMKXSA-N,WKRLQDKEXYKHJB-HFTRVMKXSA-N,1,"None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).;inhibits EVOB entry in cells / identified in network screening",Viral entry;Viral entry;Patrick;Miquel/Gemma;https://www.nature.com/articles/s41421-020-0153-3;https://stm.sciencemag.org/content/5/190/190ra79
DLZUBMGMHUNDLF-UHFFFAOYSA-N,DLZUBMGMHUNDLF-UHFFFAOYSA-N,0,"None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).",Unknown;Patrick;https://www.nature.com/articles/s41421-020-0153-3
RHMXXJGYXNZAPX-UHFFFAOYSA-N,RHMXXJGYXNZAPX-UHFFFAOYSA-N,0,"None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).",Unknown;Patrick;https://www.nature.com/articles/s41421-020-0153-3
ZCGNOVWYSGBHAU-UHFFFAOYSA-N,ZCGNOVWYSGBHAU-UHFFFAOYSA-N,3,"Developed as antiinfluenza;;Increases 7-day recovery rate in patients with COVID19;COVID-19 patients untreated with antiviral previously, favipiravir can be considered as a preferred treatment",RNA transcription or replication;RNA transcription or replication;RNA transcription or replication;RNA transcription or replication;Miquel/Gemma;Miquel/Gemma;Patrick;Martino;https://www.ncbi.nlm.nih.gov/pubmed/28769016;https://www.upi.com/Health_News/2020/02/17/China-approves-antiviral-favilavir-to-treat-coronavirus/5291581953892/;https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v1;https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v1
WHTVZRBIWZFKQO-UHFFFAOYSA-N,WHTVZRBIWZFKQO-UHFFFAOYSA-N,3,Anti SARS-CoV and MERS-CoV in vitro;Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.,Viral entry;Protease inhibitor;Miquel/Gemma;Adria;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136071;https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/16
RDOIQAHITMMDAJ-UHFFFAOYSA-N,RDOIQAHITMMDAJ-UHFFFAOYSA-N,1,Anti SARS-CoV and MERS-CoV in vitro,Unknown;Miquel/Gemma;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733787/
KJHKTHWMRKYKJE-SUGCFTRWSA-N,KJHKTHWMRKYKJE-SUGCFTRWSA-N,3,"Anti SARS-CoV and MERS-CoV in vitro / NO EFFECT IN CLINICAL TRIAL;HIV drug. Combination of Lopinavir, ritonavir and interferon beta is being evaluated in humans",Unknown;Protease inhibitor;Miquel/Gemma;Victor;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136071/;https://www.nature.com/articles/s41467-019-13940-6
ZPEIMTDSQAKGNT-UHFFFAOYSA-N,ZPEIMTDSQAKGNT-UHFFFAOYSA-N,1,Effective against SARS-CoV and MERS-CoV in vitro,Viral entry;Miquel/Gemma;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136000/
XSCGXQMFQXDFCW-UHFFFAOYSA-N,XSCGXQMFQXDFCW-UHFFFAOYSA-N,1,Effective against SARS-CoV and MERS-CoV in vitro,Viral entry;Miquel/Gemma;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136000/
KTUFNOKKBVMGRW-UHFFFAOYSA-N,KTUFNOKKBVMGRW-UHFFFAOYSA-N,1,Effective against SARS-CoV and MERS-CoV in vitro,Host factor;Miquel/Gemma;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136000/
ZBNZXTGUTAYRHI-UHFFFAOYSA-N,ZBNZXTGUTAYRHI-UHFFFAOYSA-N,1,Effective against SARS-CoV and MERS-CoV in vitro,Host factor;Miquel/Gemma;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136000/
SDUQYLNIPVEERB-QPPQHZFASA-N,SDUQYLNIPVEERB-QPPQHZFASA-N,1,Effective against SARS-CoV and MERS-CoV in vitro,Host factor;Miquel/Gemma;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136000/
BJNLLBUOHPVGFT-UHFFFAOYSA-N,BJNLLBUOHPVGFT-UHFFFAOYSA-N,1,Blocks cell entry of Covid-19 in vitro,Viral entry;Miquel/Gemma;https://www.biorxiv.org/content/10.1101/2020.02.05.935387v1.abstract
IWUCXVSUMQZMFG-AFCXAGJDSA-N,IWUCXVSUMQZMFG-AFCXAGJDSA-N,3,Combined with IFNalpha improves MERS-Cov;Drugs from Sars-Cov-2-Human PPI map,RNA transcription or replication;RNA transcription or replication;Miquel/Gemma;Victor;https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(14)70920-X/fulltext;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
JNTOCHDNEULJHD-UHFFFAOYSA-N,JNTOCHDNEULJHD-UHFFFAOYSA-N,2,Used in Herpex treatment,RNA transcription or replication;Miquel/Gemma;https://pubchem.ncbi.nlm.nih.gov/compound/Penciclovir
AMFDITJFBUXZQN-KUBHLMPHSA-N,AMFDITJFBUXZQN-KUBHLMPHSA-N,1,"High efficacy in vitro for filoviruses, under clinical trials;inhibition of virus proliferation in cell culture assays using a Vero-E6 cell line infected with MERS-CoV",RNA transcription or replication;RNA transcription or replication;Miquel/Gemma;Isabelle;https://www.ncbi.nlm.nih.gov/pubmed/24590073;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937725/
AUZONCFQVSMFAP-UHFFFAOYSA-N,AUZONCFQVSMFAP-UHFFFAOYSA-N,1,In vitro inhibition of SARS and MERS enzymes;Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,Protease inhibitor;Protease inhibitor;Miquel/Gemma;Adria;https://www.ncbi.nlm.nih.gov/pubmed/29289665;https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en
NCDNCNXCDXHOMX-XGKFQTDJSA-N,NCDNCNXCDXHOMX-XGKFQTDJSA-N,-1,Used for MERS clinically / No effect in clinical trial for Covid19,Protease inhibitor;Miquel/Gemma;https://www.nejm.org/doi/full/10.1056/NEJMoa2001282
CJBJHOAVZSMMDJ-UHFFFAOYSA-N,CJBJHOAVZSMMDJ-UHFFFAOYSA-N,1,Not clear if clinical trial ongoing;Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,Protease inhibitor;Protease inhibitor;Miquel/Gemma;Adria;https://www.pharmaceutical-technology.com/news/jj-janssen-darunavir-coronavirus/;https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en
VSZGPKBBMSAYNT-RRFJBIMHSA-N,VSZGPKBBMSAYNT-RRFJBIMHSA-N,3,"Ongoing trial, used for influenza A and B",Unknown;Miquel/Gemma;https://laegemiddelstyrelsen.dk/da/nyheder/temaer/ny-coronavirus-covid-19/~/media/5B83D25935DF43A38FF823E24604AC36.ashx
MQQNFDZXWVTQEH-UHFFFAOYSA-N,MQQNFDZXWVTQEH-UHFFFAOYSA-N,1,"effective against MERS, COVID19",Protease inhibitor;Miquel/Gemma;https://www.nature.com/articles/s41422-020-0282-0
LUKBXSAWLPMMSZ-OWOJBTEDSA-N,LUKBXSAWLPMMSZ-OWOJBTEDSA-N,1,In principle inhibits MERS infection...,Unknown;Miquel/Gemma;https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-017-2253-8
KCFYEAOKVJSACF-UHFFFAOYSA-N,KCFYEAOKVJSACF-UHFFFAOYSA-N,3,"Used in influenza treatment, only approved in Russia, clinical assays for COVID 19 ongoing;COVID-19 patients untreated with antiviral previously, favipiravir can be considered as a preferred treatment",Viral entry;Viral entry;Miquel/Gemma;Martino;https://pubmed.ncbi.nlm.nih.gov/15266832/;https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v1
XEEQGYMUWCZPDN-DOMZBBRYSA-N,XEEQGYMUWCZPDN-DOMZBBRYSA-N,1,Effective against MERS and SARS in vitro;Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,Unknown;Viral entry;Miquel/Gemma;Miquel/Gemma;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136000/;https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html
OVCDSSHSILBFBN-UHFFFAOYSA-N,OVCDSSHSILBFBN-UHFFFAOYSA-N,2,Effective against MERS and SARS in vitro / used in EBOLa;Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,Unknown;Viral entry;Miquel/Gemma;Miquel/Gemma;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136000/;https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html
UYNVMODNBIQBMV-UHFFFAOYSA-N,UYNVMODNBIQBMV-UHFFFAOYSA-N,3,Improves survival of H5N1 infected mice,Immunomodulatory;Miquel/Gemma;https://www.ncbi.nlm.nih.gov/pubmed/31822599
BSPZFJDYQHDZNR-BOSXTWCSSA-N,BSPZFJDYQHDZNR-BOSXTWCSSA-N,1,Cures a coronavirus-like disease in felines,Protease inhibitor;Miquel/Gemma;https://www.ncbi.nlm.nih.gov/pubmed/27027316
YQNQNVDNTFHQSW-UHFFFAOYSA-N,YQNQNVDNTFHQSW-UHFFFAOYSA-N,3,"Induces interferon production, works in influenza",Host factor;Miquel/Gemma;https://www.ncbi.nlm.nih.gov/pubmed/25108173
PMATZTZNYRCHOR-CGLBZJNRSA-N,PMATZTZNYRCHOR-CGLBZJNRSA-N,2,Reduces MERS infection in human in vitro ex vivo;Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,Immunomodulatory;Immunomodulatory;Miquel/Gemma;Miquel/Gemma;https://www.ncbi.nlm.nih.gov/pubmed/29772254;https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html
OLROWHGDTNFZBH-XEMWPYQTSA-N,OLROWHGDTNFZBH-XEMWPYQTSA-N,1,Prevents in vitro MERS/SARS infection but not in mouse model,Unknown;Miquel/Gemma;https://www.ncbi.nlm.nih.gov/pubmed/27840112
CYOHGALHFOKKQC-UHFFFAOYSA-N,CYOHGALHFOKKQC-UHFFFAOYSA-N,1,Inhibits MERS replication in vitro,Host factor;Miquel/Gemma;https://www.ncbi.nlm.nih.gov/pubmed/25487801
LIRYPHYGHXZJBZ-UHFFFAOYSA-N,LIRYPHYGHXZJBZ-UHFFFAOYSA-N,1,Inhibits MERS replication in vitro,Host factor;Miquel/Gemma;https://www.ncbi.nlm.nih.gov/pubmed/25487801
OUKYUETWWIPKQR-UHFFFAOYSA-N,OUKYUETWWIPKQR-UHFFFAOYSA-N,1,Inhibits MERS replication in vitro,Host factor;Miquel/Gemma;https://www.ncbi.nlm.nih.gov/pubmed/29795047
XASIMHXSUQUHLV-UHFFFAOYSA-N,XASIMHXSUQUHLV-UHFFFAOYSA-N,1,Reduce SARS-Cov2 infection in Calu2 cells.;Drugs from Sars-Cov-2-Human PPI map,Viral entry;;Adria;Victor;https://www.cell.com/cell/fulltext/S0092-8674(20)30229-4;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
SRVFFFJZQVENJC-IHRRRGAJSA-N,SRVFFFJZQVENJC-IHRRRGAJSA-N,1,Reduce SARS-2-S infection in caco2 and 293T. No data for SARS-Cov2,Viral entry;Adria;https://www.cell.com/cell/fulltext/S0092-8674(20)30229-4
RJMUSRYZPJIFPJ-UHFFFAOYSA-N,RJMUSRYZPJIFPJ-UHFFFAOYSA-N,1,"MoA: inhibits SKP2 enzyme, tested in Vero cells *BioArx / Effect validated for Sars-CoV in 2003",Host factor;Miquel/Gemma;https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html
LUKZNWIVRBCLON-GXOBDPJESA-N,LUKZNWIVRBCLON-GXOBDPJESA-N,3,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx;very small clinical trial with positive outcome,Unknown;Immunomodulatory;Miquel/Gemma;Miquel/Gemma;https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html;https://www3.nhk.or.jp/nhkworld/en/news/20200303_20/
MPMFCABZENCRHV-UHFFFAOYSA-N,MPMFCABZENCRHV-UHFFFAOYSA-N,0,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,Immunomodulatory;Miquel/Gemma;https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html
MYEJFUXQJGHEQK-ALRJYLEOSA-N,MYEJFUXQJGHEQK-ALRJYLEOSA-N,0,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,Unknown;Miquel/Gemma;https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html
WDJUZGPOPHTGOT-XUDUSOBPSA-N,WDJUZGPOPHTGOT-XUDUSOBPSA-N,0,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,Unknown;Miquel/Gemma;https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html
LTMHDMANZUZIPE-PUGKRICDSA-N,LTMHDMANZUZIPE-PUGKRICDSA-N,0,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,Unknown;Miquel/Gemma;https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html
ACGUYXCXAPNIKK-UHFFFAOYSA-N,ACGUYXCXAPNIKK-UHFFFAOYSA-N,0,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,Protease inhibitor;Miquel/Gemma;https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html
DOMWKUIIPQCAJU-LJHIYBGHSA-N,DOMWKUIIPQCAJU-LJHIYBGHSA-N,0,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,Unknown;Miquel/Gemma;https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html
KQXDHUJYNAXLNZ-XQSDOZFQSA-N,KQXDHUJYNAXLNZ-XQSDOZFQSA-N,0,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,Unknown;Miquel/Gemma;https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html
LPMXVESGRSUGHW-HBYQJFLCSA-N,LPMXVESGRSUGHW-HBYQJFLCSA-N,0,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,Unknown;Miquel/Gemma;https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html
YVPXVXANRNDGTA-WDYNHAJCSA-N,YVPXVXANRNDGTA-WDYNHAJCSA-N,0,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,Unknown;Miquel/Gemma;https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html
JYWIYHUXVMAGLG-UHFFFAOYSA-N,JYWIYHUXVMAGLG-UHFFFAOYSA-N,0,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,Unknown;Miquel/Gemma;https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html
JHVAMHSQVVQIOT-MFAJLEFUSA-N,JHVAMHSQVVQIOT-MFAJLEFUSA-N,0,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,Unknown;Miquel/Gemma;https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html
GYQYAJJFPNQOOW-UHFFFAOYSA-N,GYQYAJJFPNQOOW-UHFFFAOYSA-N,0,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,Host factor;Miquel/Gemma;https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html
DFOCUWZXJBAUSQ-URLMMPGGSA-N,DFOCUWZXJBAUSQ-URLMMPGGSA-N,0,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,Unknown;Miquel/Gemma;https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html
WVTKBKWTSCPRNU-KYJUHHDHSA-N,WVTKBKWTSCPRNU-KYJUHHDHSA-N,0,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,Unknown;Miquel/Gemma;https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html
UZWDCWONPYILKI-UHFFFAOYSA-N,UZWDCWONPYILKI-UHFFFAOYSA-N,0,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,Host factor;Miquel/Gemma;https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html
PURKAOJPTOLRMP-UHFFFAOYSA-N,PURKAOJPTOLRMP-UHFFFAOYSA-N,0,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,Host factor;Miquel/Gemma;https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html
UCJGJABZCDBEDK-UHFFFAOYSA-N,UCJGJABZCDBEDK-UHFFFAOYSA-N,0,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,Unknown;Miquel/Gemma;https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html
SVOQIEJWJCQGDQ-UHFFFAOYSA-N,SVOQIEJWJCQGDQ-UHFFFAOYSA-N,0,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,Unknown;Miquel/Gemma;https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html
IACQCQDWSIQSRP-ZCFIWIBFSA-N,IACQCQDWSIQSRP-ZCFIWIBFSA-N,0,Inhibition of RdRp in polymerase extension experiment *BioArx,RNA transcription or replication;Miquel/Gemma;https://www.biorxiv.org/content/10.1101/2020.03.18.997585v1.full.pdf+html
TTZHDVOVKQGIBA-IAAJYNJHSA-N,TTZHDVOVKQGIBA-IAAJYNJHSA-N,0,Inhibition of RdRp in polymerase extension experiment *BioArx,RNA transcription or replication;Miquel/Gemma;https://www.biorxiv.org/content/10.1101/2020.03.18.997585v1.full.pdf+html
UNKRRBWXJZNMAN-XLPZGREQSA-N,UNKRRBWXJZNMAN-XLPZGREQSA-N,0,Inhibition of RdRp in polymerase extension experiment *BioArx,RNA transcription or replication;Miquel/Gemma;https://www.biorxiv.org/content/10.1101/2020.03.18.997585v1.full.pdf+html
GLWHPRRGGYLLRV-XLPZGREQSA-N,GLWHPRRGGYLLRV-XLPZGREQSA-N,0,Inhibition of RdRp in polymerase extension experiment *BioArx,RNA transcription or replication;Miquel/Gemma;https://www.biorxiv.org/content/10.1101/2020.03.18.997585v1.full.pdf+html
AXRYRYVKAWYZBR-GASGPIRDSA-N,AXRYRYVKAWYZBR-GASGPIRDSA-N,0,"None, computational (MoA: inhibitor 3CLp) *BioArx",Protease inhibitor;Miquel/Gemma;https://www.biorxiv.org/content/10.1101/2020.01.31.929547v1
XPOQHMRABVBWPR-ZDUSSCGKSA-N,XPOQHMRABVBWPR-ZDUSSCGKSA-N,0,"None, computational (MoA: inhibitor 3CLp) *BioArx",RNA transcription or replication;Miquel/Gemma;https://www.biorxiv.org/content/10.1101/2020.01.31.929547v1
XUZMWHLSFXCVMG-UHFFFAOYSA-N,XUZMWHLSFXCVMG-UHFFFAOYSA-N,0,affinity AAK-1 binding drug,Immunomodulatory;Victor;https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30304-4/fulltext
FHCUMDQMBHQXKK-UHFFFAOYSA-N,FHCUMDQMBHQXKK-UHFFFAOYSA-N,0,NS5A inhibtors in HCV found through Virtual Screening,RNA transcription or replication;Adria;https://f1000research.com/articles/9-129/v1
VRTWBAAJJOHBQU-UHFFFAOYSA-N,VRTWBAAJJOHBQU-UHFFFAOYSA-N,0,NS5A inhibtors in HCV found through Virtual Screening,RNA transcription or replication;Adria;https://f1000research.com/articles/9-129/v1
FSVJFNAIGNNGKK-UHFFFAOYSA-N,FSVJFNAIGNNGKK-UHFFFAOYSA-N,0,Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.,Protease inhibitor;Adria;https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/2
VDHAWDNDOKGFTD-UHFFFAOYSA-N,VDHAWDNDOKGFTD-UHFFFAOYSA-N,0,Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.,Protease inhibitor;Adria;https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/3
REQCZEXYDRLIBE-UHFFFAOYSA-N,REQCZEXYDRLIBE-UHFFFAOYSA-N,0,Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.,Protease inhibitor;Adria;https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/4
DOMXUEMWDBAQBQ-UHFFFAOYSA-N,DOMXUEMWDBAQBQ-UHFFFAOYSA-N,0,Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.,Protease inhibitor;Adria;https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/5
XADCESSVHJOZHK-UHFFFAOYSA-N,XADCESSVHJOZHK-UHFFFAOYSA-N,0,Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.,Protease inhibitor;Adria;https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/6
SGUAFYQXFOLMHL-UHFFFAOYSA-N,SGUAFYQXFOLMHL-UHFFFAOYSA-N,0,Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.,Protease inhibitor;Adria;https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/7
BYJAVTDNIXVSPW-UHFFFAOYSA-N,BYJAVTDNIXVSPW-UHFFFAOYSA-N,0,Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.,Protease inhibitor;Adria;https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/8
PHWBOXQYWZNQIN-UHFFFAOYSA-N,PHWBOXQYWZNQIN-UHFFFAOYSA-N,0,Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.,Protease inhibitor;Adria;https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/9
HLFSDGLLUJUHTE-SNVBAGLBSA-N,HLFSDGLLUJUHTE-SNVBAGLBSA-N,0,Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.,Protease inhibitor;Adria;https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/11
KRMDCWKBEZIMAB-UHFFFAOYSA-N,KRMDCWKBEZIMAB-UHFFFAOYSA-N,0,Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.,Protease inhibitor;Adria;https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/12
CNIIGCLFLJGOGP-UHFFFAOYSA-N,CNIIGCLFLJGOGP-UHFFFAOYSA-N,0,Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.,Protease inhibitor;Adria;https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/13
BPZSYCZIITTYBL-UHFFFAOYSA-N,BPZSYCZIITTYBL-UHFFFAOYSA-N,0,Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.,Protease inhibitor;Adria;https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/14
JGSARLDLIJGVTE-MBNYWOFBSA-N,JGSARLDLIJGVTE-MBNYWOFBSA-N,0,Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.,Protease inhibitor;Adria;https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/15
JBMKAUGHUNFTOL-UHFFFAOYSA-N,JBMKAUGHUNFTOL-UHFFFAOYSA-N,0,Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.,Protease inhibitor;Adria;https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/17
CBVCZFGXHXORBI-UHFFFAOYSA-N,CBVCZFGXHXORBI-UHFFFAOYSA-N,0,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,Protease inhibitor;Adria;https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en
QWAXKHKRTORLEM-UHFFFAOYSA-N,QWAXKHKRTORLEM-UHFFFAOYSA-N,0,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,Protease inhibitor;Adria;https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en
KJHKTHWMRKYKJE-UHFFFAOYSA-N,KJHKTHWMRKYKJE-UHFFFAOYSA-N,0,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,Protease inhibitor;Adria;https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en
BLMPQMFVWMYDKT-UHFFFAOYSA-N,BLMPQMFVWMYDKT-UHFFFAOYSA-N,0,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,Host factor;Adria;https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en
AXRYRYVKAWYZBR-UHFFFAOYSA-N,AXRYRYVKAWYZBR-UHFFFAOYSA-N,0,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,Protease inhibitor;Adria;https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en
MYXACKZCYFKMTE-JETRDCLMSA-N,MYXACKZCYFKMTE-JETRDCLMSA-N,0,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,Protease inhibitor;Adria;https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en
MLBVMOWEQCZNCC-UHFFFAOYSA-N,MLBVMOWEQCZNCC-UHFFFAOYSA-N,0,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,Protease inhibitor;Adria;https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en
MCGSCOLBFJQGHM-UHFFFAOYSA-N,MCGSCOLBFJQGHM-UHFFFAOYSA-N,0,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,RNA transcription or replication;Adria;https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en
JUZYLCPPVHEVSV-UHFFFAOYSA-N,JUZYLCPPVHEVSV-UHFFFAOYSA-N,0,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,Unknown;Adria;https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en
KJFBVJALEQWJBS-XUXIUFHCSA-N,KJFBVJALEQWJBS-XUXIUFHCSA-N,0,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,Unknown;Adria;https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en
CZFFBEXEKNGXKS-UHFFFAOYSA-N,CZFFBEXEKNGXKS-UHFFFAOYSA-N,0,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,Unknown;Adria;https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en
UCHDWCPVSPXUMX-UHFFFAOYSA-N,UCHDWCPVSPXUMX-UHFFFAOYSA-N,0,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,Immunomodulatory;Adria;https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en
MFMQRDLLSRLUJY-YMQHIKHWSA-N,MFMQRDLLSRLUJY-YMQHIKHWSA-N,0,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,Unknown;Adria;https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en
HSTZMXCBWJGKHG-UHFFFAOYSA-N,HSTZMXCBWJGKHG-UHFFFAOYSA-N,0,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,Unknown;Adria;https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en
DQFBYFPFKXHELB-UHFFFAOYSA-N,DQFBYFPFKXHELB-UHFFFAOYSA-N,0,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,Unknown;Adria;https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en
AOCCBINRVIKJHY-UHFFFAOYSA-N,AOCCBINRVIKJHY-UHFFFAOYSA-N,0,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,RNA transcription or replication;Adria;https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en
NEZONWMXZKDMKF-UHFFFAOYSA-N,NEZONWMXZKDMKF-UHFFFAOYSA-N,0,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,Unknown;Adria;https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en
PMJIHLSCWIDGMD-UHFFFAOYSA-N,PMJIHLSCWIDGMD-UHFFFAOYSA-N,0,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,Unknown;Adria;https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en
BPBPYQWMFCTCNG-UHFFFAOYSA-N,BPBPYQWMFCTCNG-UHFFFAOYSA-N,0,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,Unknown;Adria;https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en
JDSJDASOXWCHPN-UHFFFAOYSA-N,JDSJDASOXWCHPN-UHFFFAOYSA-N,0,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,Host factor;Adria;https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en
PMATZTZNYRCHOR-UHFFFAOYSA-N,PMATZTZNYRCHOR-UHFFFAOYSA-N,0,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,Unknown;Adria;https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en
RSUVYMGADVXGOU-BUHFOSPRSA-N,RSUVYMGADVXGOU-BUHFOSPRSA-N,0,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,Protease inhibitor;Adria;https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en
DNVXATUJJDPFDM-KRWDZBQOSA-N,DNVXATUJJDPFDM-KRWDZBQOSA-N,0,Drugs from Sars-Cov-2-Human PPI map,Host factor;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
NETXMUIMUZJUTB-UHFFFAOYSA-N,NETXMUIMUZJUTB-UHFFFAOYSA-N,0,Drugs from Sars-Cov-2-Human PPI map,Host factor;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
MUOKSQABCJCOPU-UHFFFAOYSA-N,MUOKSQABCJCOPU-UHFFFAOYSA-N,0,Drugs from Sars-Cov-2-Human PPI map,Host factor;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
PHAOTASRLQMKBE-UHFFFAOYSA-N,PHAOTASRLQMKBE-UHFFFAOYSA-N,0,Drugs from Sars-Cov-2-Human PPI map,Host factor;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
JWOGUUIOCYMBPV-LQJYRIKDSA-N,JWOGUUIOCYMBPV-LQJYRIKDSA-N,0,Drugs from Sars-Cov-2-Human PPI map,Unknown;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
NIJJYAXOARWZEE-UHFFFAOYSA-N,NIJJYAXOARWZEE-UHFFFAOYSA-N,0,Drugs from Sars-Cov-2-Human PPI map,Unknown;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
XDHNQDDQEHDUTM-UHFFFAOYSA-N,XDHNQDDQEHDUTM-UHFFFAOYSA-N,0,Drugs from Sars-Cov-2-Human PPI map,Viral entry;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
DGPGXHRHNRYVDH-UHFFFAOYSA-N,DGPGXHRHNRYVDH-UHFFFAOYSA-N,0,Drugs from Sars-Cov-2-Human PPI map,Host factor;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
FOQRKFCLRMMKAT-UHFFFAOYSA-N,FOQRKFCLRMMKAT-UHFFFAOYSA-N,0,Drugs from Sars-Cov-2-Human PPI map,Host factor;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
BDSYECBSUUOPCT-UHFFFAOYSA-N,BDSYECBSUUOPCT-UHFFFAOYSA-N,0,Drugs from Sars-Cov-2-Human PPI map,Unknown;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
PHRCDWVPTULQMT-UHFFFAOYSA-N,PHRCDWVPTULQMT-UHFFFAOYSA-N,0,Drugs from Sars-Cov-2-Human PPI map,Unknown;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
LNEPOXFFQSENCJ-UHFFFAOYSA-N,LNEPOXFFQSENCJ-UHFFFAOYSA-N,0,Drugs from Sars-Cov-2-Human PPI map,Unknown;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
JRURYQJSLYLRLN-BJMVGYQFSA-N,JRURYQJSLYLRLN-BJMVGYQFSA-N,0,Drugs from Sars-Cov-2-Human PPI map,Unknown;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
CGIGDMFJXJATDK-UHFFFAOYSA-N,CGIGDMFJXJATDK-UHFFFAOYSA-N,0,Drugs from Sars-Cov-2-Human PPI map,Immunomodulatory;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
XZWYZXLIPXDOLR-UHFFFAOYSA-N,XZWYZXLIPXDOLR-UHFFFAOYSA-N,0,Drugs from Sars-Cov-2-Human PPI map,Unknown;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
PHXJVRSECIGDHY-UHFFFAOYSA-N,PHXJVRSECIGDHY-UHFFFAOYSA-N,0,Drugs from Sars-Cov-2-Human PPI map,Host factor;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
ZKZXNDJNWUTGDK-NSCUHMNNSA-N,ZKZXNDJNWUTGDK-NSCUHMNNSA-N,0,Drugs from Sars-Cov-2-Human PPI map,Host factor;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
JBPUGFODGPKTDW-SFHVURJKSA-N,JBPUGFODGPKTDW-SFHVURJKSA-N,0,Drugs from Sars-Cov-2-Human PPI map,Host factor;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
LXBIFEVIBLOUGU-DPYQTVNSSA-N,LXBIFEVIBLOUGU-DPYQTVNSSA-N,0,Drugs from Sars-Cov-2-Human PPI map,Host factor;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
HPNSFSBZBAHARI-RUDMXATFSA-N,HPNSFSBZBAHARI-RUDMXATFSA-N,0,Drugs from Sars-Cov-2-Human PPI map,Immunomodulatory;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
JJWLXRKVUJDJKG-VIFPVBQESA-N,JJWLXRKVUJDJKG-VIFPVBQESA-N,0,Drugs from Sars-Cov-2-Human PPI map,Host factor;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
BMGQWWVMWDBQGC-IIFHNQTCSA-N,BMGQWWVMWDBQGC-IIFHNQTCSA-N,0,Drugs from Sars-Cov-2-Human PPI map,Host factor;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
HFNKQEVNSGCOJV-OAHLLOKOSA-N,HFNKQEVNSGCOJV-OAHLLOKOSA-N,0,Drugs from Sars-Cov-2-Human PPI map,Host factor;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
UCUHFWIFSHROPY-RWPZCVJISA-N,UCUHFWIFSHROPY-RWPZCVJISA-N,0,Drugs from Sars-Cov-2-Human PPI map,Host factor;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
STQGQHZAVUOBTE-VGBVRHCVSA-N,STQGQHZAVUOBTE-VGBVRHCVSA-N,0,Drugs from Sars-Cov-2-Human PPI map,Unknown;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
SGTNSNPWRIOYBX-UHFFFAOYSA-N,SGTNSNPWRIOYBX-UHFFFAOYSA-N,0,Drugs from Sars-Cov-2-Human PPI map,Unknown;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
GCWIQUVXWZWCLE-INIZCTEOSA-N,GCWIQUVXWZWCLE-INIZCTEOSA-N,0,Drugs from Sars-Cov-2-Human PPI map,Host factor;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
GYLDXIAOMVERTK-UHFFFAOYSA-N,GYLDXIAOMVERTK-UHFFFAOYSA-N,0,Drugs from Sars-Cov-2-Human PPI map,Host factor;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
BFSMGDJOXZAERB-UHFFFAOYSA-N,BFSMGDJOXZAERB-UHFFFAOYSA-N,0,Drugs from Sars-Cov-2-Human PPI map,Host factor;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
ONJZYZYZIKTIEG-CFBQITSMSA-N,ONJZYZYZIKTIEG-CFBQITSMSA-N,0,Drugs from Sars-Cov-2-Human PPI map,Immunomodulatory;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
QJJXYPPXXYFBGM-LFZNUXCKSA-N,QJJXYPPXXYFBGM-LFZNUXCKSA-N,0,Drugs from Sars-Cov-2-Human PPI map,Immunomodulatory;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
MPUQHZXIXSTTDU-QXGSTGNESA-N,MPUQHZXIXSTTDU-QXGSTGNESA-N,0,Drugs from Sars-Cov-2-Human PPI map,Host factor;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
WOBPZFKXPCYOLU-YBFXNURJSA-N,WOBPZFKXPCYOLU-YBFXNURJSA-N,0,Drugs from Sars-Cov-2-Human PPI map,;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
FAKRSMQSSFJEIM-RQJHMYQMSA-N,FAKRSMQSSFJEIM-RQJHMYQMSA-N,0,Drugs from Sars-Cov-2-Human PPI map,;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
RLAWWYSOJDYHDC-BZSNNMDCSA-N,RLAWWYSOJDYHDC-BZSNNMDCSA-N,0,Drugs from Sars-Cov-2-Human PPI map,;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
WIIZWVCIJKGZOK-RKDXNWHRSA-N,WIIZWVCIJKGZOK-RKDXNWHRSA-N,0,Drugs from Sars-Cov-2-Human PPI map,;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
CGZOGNUFXMNYEI-UDUHKTKDSA-N,CGZOGNUFXMNYEI-UDUHKTKDSA-N,0,Drugs from Sars-Cov-2-Human PPI map,;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
TYZROVQLWOKYKF-ZDUSSCGKSA-N,TYZROVQLWOKYKF-ZDUSSCGKSA-N,0,Drugs from Sars-Cov-2-Human PPI map,;Victor;https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf
